IBDEI0YS ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16339,0)
 ;;=C79.52^^64^739^31
 ;;^UTILITY(U,$J,358.3,16339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16339,1,3,0)
 ;;=3^Secondary Malig Neop  Bone Marrow
 ;;^UTILITY(U,$J,358.3,16339,1,4,0)
 ;;=4^C79.52
 ;;^UTILITY(U,$J,358.3,16339,2)
 ;;=^5001351
 ;;^UTILITY(U,$J,358.3,16340,0)
 ;;=C92.00^^64^739^25
 ;;^UTILITY(U,$J,358.3,16340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16340,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16340,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,16340,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,16341,0)
 ;;=C92.40^^64^739^30
 ;;^UTILITY(U,$J,358.3,16341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16341,1,3,0)
 ;;=3^Promyelocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16341,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,16341,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,16342,0)
 ;;=C92.50^^64^739^27
 ;;^UTILITY(U,$J,358.3,16342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16342,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16342,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,16342,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,16343,0)
 ;;=C78.7^^64^739^36
 ;;^UTILITY(U,$J,358.3,16343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16343,1,3,0)
 ;;=3^Secondary Malig Neop Liver & Intrahepatic Bile Duct
 ;;^UTILITY(U,$J,358.3,16343,1,4,0)
 ;;=4^C78.7
 ;;^UTILITY(U,$J,358.3,16343,2)
 ;;=^5001339
 ;;^UTILITY(U,$J,358.3,16344,0)
 ;;=C91.10^^64^739^4
 ;;^UTILITY(U,$J,358.3,16344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16344,1,3,0)
 ;;=3^Lymphocytic Leukemia B-Cell Type,Chronic,Not in Remission
 ;;^UTILITY(U,$J,358.3,16344,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,16344,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,16345,0)
 ;;=D46.9^^64^739^26
 ;;^UTILITY(U,$J,358.3,16345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16345,1,3,0)
 ;;=3^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,16345,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,16345,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,16346,0)
 ;;=C79.31^^64^739^33
 ;;^UTILITY(U,$J,358.3,16346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16346,1,3,0)
 ;;=3^Secondary Malig Neop Brain
 ;;^UTILITY(U,$J,358.3,16346,1,4,0)
 ;;=4^C79.31
 ;;^UTILITY(U,$J,358.3,16346,2)
 ;;=^5001347
 ;;^UTILITY(U,$J,358.3,16347,0)
 ;;=C79.32^^64^739^34
 ;;^UTILITY(U,$J,358.3,16347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16347,1,3,0)
 ;;=3^Secondary Malig Neop Cerebral Meninges
 ;;^UTILITY(U,$J,358.3,16347,1,4,0)
 ;;=4^C79.32
 ;;^UTILITY(U,$J,358.3,16347,2)
 ;;=^5001348
 ;;^UTILITY(U,$J,358.3,16348,0)
 ;;=G89.3^^64^739^28
 ;;^UTILITY(U,$J,358.3,16348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16348,1,3,0)
 ;;=3^Neoplasm Related Pain
 ;;^UTILITY(U,$J,358.3,16348,1,4,0)
 ;;=4^G89.3
 ;;^UTILITY(U,$J,358.3,16348,2)
 ;;=^5004159
 ;;^UTILITY(U,$J,358.3,16349,0)
 ;;=C79.82^^64^739^35
 ;;^UTILITY(U,$J,358.3,16349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16349,1,3,0)
 ;;=3^Secondary Malig Neop Genital Organs
 ;;^UTILITY(U,$J,358.3,16349,1,4,0)
 ;;=4^C79.82
 ;;^UTILITY(U,$J,358.3,16349,2)
 ;;=^267339
 ;;^UTILITY(U,$J,358.3,16350,0)
 ;;=I50.9^^64^740^7
 ;;^UTILITY(U,$J,358.3,16350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16350,1,3,0)
 ;;=3^Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,16350,1,4,0)
 ;;=4^I50.9
 ;;^UTILITY(U,$J,358.3,16350,2)
 ;;=^5007251
 ;;^UTILITY(U,$J,358.3,16351,0)
 ;;=I73.9^^64^740^13
 ;;^UTILITY(U,$J,358.3,16351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16351,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16351,1,4,0)
 ;;=4^I73.9
